Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 200,000 shares, a growth of 32.4% from the August 15th total of 151,100 shares. Based on an average daily trading volume, of 72,500 shares, the short-interest ratio is currently 2.8 days. Currently, 1.2% of the company’s stock are short sold.

Analysts Set New Price Targets

Several analysts have recently commented on CYTH shares. HC Wainwright reissued a “neutral” rating and issued a $0.95 price target (down from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Ascendiant Capital Markets lowered their target price on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a report on Monday, August 26th. Finally, Maxim Group reissued a “hold” rating on shares of Cyclo Therapeutics in a research note on Tuesday, August 27th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund VI Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics accounts for approximately 1.4% of Founders Fund VI Management LLC’s portfolio, making the stock its 2nd biggest holding. Founders Fund VI Management LLC owned approximately 0.48% of Cyclo Therapeutics as of its most recent SEC filing. 68.55% of the stock is owned by hedge funds and other institutional investors.

Cyclo Therapeutics Price Performance

Shares of NASDAQ CYTH remained flat at $0.64 during mid-day trading on Monday. The stock had a trading volume of 20,663 shares, compared to its average volume of 78,459. Cyclo Therapeutics has a twelve month low of $0.59 and a twelve month high of $2.12. The firm has a market cap of $18.37 million, a PE ratio of -0.64 and a beta of -0.38. The business’s 50-day moving average is $1.03 and its 200 day moving average is $1.25.

Cyclo Therapeutics (NASDAQ:CYTH) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million. Cyclo Therapeutics had a negative return on equity of 2,741.89% and a negative net margin of 1,830.27%. As a group, equities analysts expect that Cyclo Therapeutics will post -0.66 EPS for the current fiscal year.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.